Mushumo weNyaya Yemhinduro Yenguva Refu MuHepatocellular Carcinoma KumaGPC3 CAR T Cells (CT011)

CT011 chigadzirwa cheGPC3 CAR T-cell chinoda kurapwa kwehepatocellular carcinoma (HCC). CT011 yakapihwa mvumo yeIND kubva kuNMPA muna 2019 yekurapa varwere vane GPC3-positive solid bundu, iro raive mvumo yekutanga yeIND yekurapa CAR T-cell kurwisa mabundu akaomarara muChina.

Nyamavhuvhu 18, 2022, CARsgen Therapeutics inozivisa kuti mushumo wenyaya, une musoro unoti "Long Term Complete Response of Advanced Hepatocellular Carcinoma to Glypican-3 Specific Chimeric Antigen Receptor T-Cells plus Sorafenib, Mushumo wenyaya", wakabudiswa muFrontiers in Immunology.

Nyaya iyi yakaratidza murwere wechirume wekuAsia ane makore makumi matanhatu ekuberekwa ane HCC ine chekuita nehepatitis B virus (HBV) uyo akavhiyiwa muna Chivabvu 2018. Muna Nyamavhuvhu 2018, kudzoka kwekenza yechiropa uye metastasis yemapapu kwakaitika mushure mekuvhiyiwa, uye akazopihwa transarterial chemoembolization (TACE) yekurapa maronda echiropa uye interventional ablation yekurapa metastases yemapapu. Mwedzi miviri gare gare, akafambira mberi uye akanyoreswa mukiriniki. Mushure mekunyoreswa, murwere akanyoreswa leukapheresis yekugadzira CAR-GPC3 T-cell. Mazuva manomwe mushure me leukapheresis, murwere akatanga kugamuchira 400 mg ye sorafenib kaviri pazuva. Murwere akagamuchira 4 cycles yeCAR-GPC3 T cells (CT011) uye cycle yega yega yakakamurwa kuita infusions mbiri. Pamberi pe cycle yega yega yeCT011 kurapwa, lymphodepletion yakaitwa. Huwandu hwe4×10⁹Masero eCAR-GPC3 T akaiswa mukati.

Kurapa kwakabatana kweCT011 pamwe nesorafenib kwaishivirira zvakanaka. Murwere uyu akawana mhinduro dzisina kukwana (PR) kubva pamwedzi wechitatu uye akawana CR mumwedzi wegumi nemiviri mushure mekuiswa kwekutanga kweCT011. Bundu iri harina kuramba richikura kweanopfuura mwedzi makumi matatu nematanhatu uye rakaramba riri CR kweanopfuura mwedzi makumi maviri nemana mushure mekuiswa kwekutanga.

Sekuziva kwedu, iyi ndiyo nyaya yekutanga yakataurwa ine CR mushure mekurapwa kweCAR T cells netyrosine kinase inhibitors. Zvakabuda mukiriniki zvakaratidza kuti kusanganiswa kweGPC3 CAR T-cell neSorafenib kungave nzira itsva inovimbisa varwere veHCC vane GPC3+ yepamusoro.

Parizvino, kune mimwe miedzo yakawanda yeCAR-T muChina, uye vari kutsvaga varwere. Kuti muwane mazano pamusoro pemishonga mitsva netekinoroji, munogona kubata Beijing South Region Oncology Hospital International Department.

Nhamba yefoni: 4008803716

Email：myimmnet@163.com